There have already been exceptional post-marketing experiences of cases of intestinal obstruction, and exacerbation of diverticulitis, a few of which have necessary clinical intervention to eliminate the tablet. Patients with fundamental GI disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at higher danger